Incannex Healthcare Limited
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a IXHL research report →
Price Chart
About the company
Incannex Healthcare Limited is an Australian company dedicated to the research, development, and commercialization of medicinal cannabinoid products. The firm offers pharmaceutical-grade cannabinoid compounds under its proprietary Incannex brand. Its product pipeline includes several key assets: IHL-42X: This compound is currently undergoing Phase II clinical evaluation for the treatment of obstructive sleep apnea (OSA).
- CEO
- Joel Bradley Latham
- IPO
- 2022
- Employees
- 12
- HQ
- Melbourne, VIC, AU
Get TickerSpark's AI analysis on IXHL
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $37.93M
- P/E
- -2.83
- PEG
- -0.09
- P/S
- 0.00
- P/B
- 0.58
- EV/EBITDA
- 1.30
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -27.42%
- ROIC
- -22.62%
Latest fiscal year · YoY change
- Revenue
- $0-100.0%
- Gross Profit
- $-240,000-50.0%
- Op Income
- $-23,027,000
- Net Income
- $-19,302,000+58.8%
- EPS
- $-1.66+95.9%
- OCF Growth
- -2.8%
- FCF Growth
- -2.8%
- 52W High
- $14.91
- 52W Low
- $2.49
- 50D MA
- $3.31
- 200D MA
- $5.06
- Beta
- 2.82
- RSI (14)
- 42
- Avg Volume
- 106.41K
No earnings-call transcripts are available for IXHL yet.
- Free Float
- 82.5%
- Shares Outstanding
- 11.96M
- Float Shares
- 9.87M
of shares held by institutions
20 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Lpl Financial LLC | 148.18K | ▲ 77.00K |
| Millennium Management LLC | 95.25K | ▲ 95.25K |
| Jane Street Group, LLC | 78.19K | ▲ 78.19K |
| Advisorshares Investments LLC | 60.87K | ▲ 36.37K |
| Susquehanna International Group, Llp | 28.77K | ▲ 28.77K |
| Commonwealth Equity Services, LLC | 14.03K | ▲ 1.92K |
| Citadel Advisors LLC | 10.35K | ▲ 10.35K |
| Advisor Group Holdings, Inc. | 6.38K | 0 |
| Ubs Group AG | 3.61K | ▼ 36.76K |
| Morgan Stanley | 3.56K | ▲ 1.49K |
| Citigroup Inc | 2.81K | ▲ 2.81K |
| Quent Capital, LLC | 1.93K | 0 |
Held by 2 ETFs
Biggest fund positions in IXHL by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 14, 25 | Valentine Troy | other | 11,302,608 |
| Nov 14, 25 | Clark Robert | other | 1,686,956 |
| Nov 14, 25 | Widdows Peter | other | 1,686,956 |
| Nov 14, 25 | Swan Joseph | other | 869,565 |
| Nov 14, 25 | Latham Joel | other | 22,608,692 |
| Nov 14, 25 | Anastassov George | other | 1,686,956 |
| Oct 23, 24 | Barbato Luigi M. | other | 100,476 |
| Oct 21, 24 | Barbato Luigi M. | other | 0 |
| May 6, 24 | Swan Joseph | other | 50,793 |
| Jun 30, 24 | Swan Joseph | other | 0 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our IXHL coverage
Recent articles, reports, and earnings notes.
No research on IXHL yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate IXHL report →Stonegate Updates Coverage on Incannex Healthcare Inc. (IXHL) FY26
newsfilecorp.com · Oct 1
Head to Head Survey: Scilex (NASDAQ:SCLX) versus Incannex Healthcare (NASDAQ:IXHL)
defenseworld.net · Sep 26
Incannex Healthcare Provides Corporate Update on Clinical Progress, Intellectual Property and Capital Position
globenewswire.com · Sep 9
Incannex Announces First Patient Dosed in DReAMzz Phase 2 Study of IHL-42X
globenewswire.com · Aug 25
Incannex Commences Participant Screening in DReAMzz Phase 2 Study of IHL-42X for Obstructive Sleep Apnea
globenewswire.com · Jul 23
Incannex Secures U.S. Patent Grant for IHL-42X in Obstructive Sleep Apnea
globenewswire.com · Jun 25
Incannex Receives A$6.0 Million R&D Tax Incentive Refund for FY25, Further Strengthening Balance Sheet and Financial Flexibility
globenewswire.com · Jun 10
Incannex Receives A$6.0 Million R&D Tax Incentive Refund for FY25, Further Strengthening Balance Sheet and Financial Flexibility
globenewswire.com · Jun 10
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.